Roundtable: Europe (1) - The Experimental Use Exemption, the Bolar Exemption and the SPC Manufacturing Waiver and Their Interplay and How the Expanded Bolar Exemption Is Likely to Impact IP Enforcement Strategy

19 Jan 2027
Pharma & Biotech Roundtables
Speakers
Aoife Murphy
Aoife Murphy, Partner - DLA Piper
Kokularajah Paheenthararajah
Kokularajah Paheenthararajah, DLA Piper - Partner